Regen BioPharma, Inc.
RGBP
$0.026
$0.000.00%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| SG&A Expenses | 6.97% | 23.57% | 16.50% | -29.56% | -34.55% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.20% | 0.15% | 1.85% | -29.12% | -34.79% |
| Operating Income | 22.79% | -0.24% | -3.18% | 39.11% | 46.12% |
| Income Before Tax | -33.84% | -34.44% | -65.50% | -157.28% | -151.48% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -33.84% | -34.44% | -65.50% | -157.28% | -151.48% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -33.84% | -34.44% | -65.50% | -157.28% | -151.48% |
| EBIT | 22.79% | -0.24% | -3.18% | 39.11% | 46.12% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -19.82% | -56.07% | -102.63% | -187.16% | -178.53% |
| Normalized Basic EPS | -15.18% | -49.10% | -92.29% | -175.93% | -195.36% |
| EPS Diluted | -19.82% | -56.07% | -102.63% | -187.16% | -178.53% |
| Normalized Diluted EPS | -15.18% | -49.10% | -92.29% | -175.93% | -195.36% |
| Average Basic Shares Outstanding | 192.33% | 72.61% | -1.28% | -15.75% | -11.94% |
| Average Diluted Shares Outstanding | 192.33% | 72.61% | -1.28% | -15.75% | -11.94% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |